Annual EBIT
$14.65 B
+$4.67 B+46.78%
December 31, 2024
Summary
- As of February 7, 2025, NVS annual earnings before interest & taxes is $14.65 billion, with the most recent change of +$4.67 billion (+46.78%) on December 31, 2024.
- During the last 3 years, NVS annual EBIT has fallen by -$10.67 billion (-42.15%).
- NVS annual EBIT is now -42.15% below its all-time high of $25.32 billion, reached on December 31, 2021.
Performance
NVS EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
$3.56 B
-$89.00 M-2.44%
December 31, 2024
Summary
- As of February 7, 2025, NVS quarterly earnings before interest & taxes is $3.56 billion, with the most recent change of -$89.00 million (-2.44%) on December 31, 2024.
- Over the past year, NVS quarterly EBIT has increased by +$966.00 million (+37.24%).
- NVS quarterly EBIT is now -77.07% below its all-time high of $15.53 billion, reached on December 31, 2021.
Performance
NVS Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
$14.65 B
+$966.00 M+7.06%
December 31, 2024
Summary
- As of February 7, 2025, NVS TTM earnings before interest & taxes is $14.65 billion, with the most recent change of +$966.00 million (+7.06%) on December 31, 2024.
- Over the past year, NVS TTM EBIT has increased by +$4.67 billion (+46.78%).
- NVS TTM EBIT is now -42.64% below its all-time high of $25.54 billion, reached on March 31, 2022.
Performance
NVS TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
NVS EBIT Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +46.8% | +37.2% | +46.8% |
3 y3 years | -42.1% | +100.7% | +59.9% |
5 y5 years | +49.6% | +100.7% | +59.9% |
NVS EBIT Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -42.1% | +83.6% | -77.1% | +100.7% | -42.6% | +71.6% |
5 y | 5-year | -42.1% | +83.6% | -77.1% | +100.7% | -42.6% | +71.6% |
alltime | all time | -42.1% | +217.7% | -77.1% | +132.4% | -42.6% | +939.3% |
Novartis AG EBIT History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | $14.65 B(+46.8%) | $3.56 B(-2.4%) | $14.65 B(+7.1%) |
Sep 2024 | - | $3.65 B(-10.7%) | $13.68 B(+15.9%) |
Jun 2024 | - | $4.09 B(+22.0%) | $11.80 B(+11.3%) |
Mar 2024 | - | $3.35 B(+29.1%) | $10.61 B(+6.3%) |
Dec 2023 | $9.98 B(+25.1%) | $2.59 B(+46.2%) | $9.98 B(+8.9%) |
Sep 2023 | - | $1.77 B(-38.6%) | $9.16 B(-0.2%) |
Jun 2023 | - | $2.89 B(+6.3%) | $9.18 B(+7.6%) |
Mar 2023 | - | $2.72 B(+53.2%) | $8.53 B(-1.7%) |
Dec 2022 | $7.98 B(-68.5%) | $1.78 B(-0.9%) | $8.68 B(-61.3%) |
Sep 2022 | - | $1.79 B(-20.1%) | $22.43 B(-6.8%) |
Jun 2022 | - | $2.24 B(-21.8%) | $24.07 B(-5.7%) |
Mar 2022 | - | $2.87 B(-81.5%) | $25.54 B(+0.9%) |
Dec 2021 | $25.32 B(+135.6%) | $15.53 B(+352.4%) | $25.32 B(+101.7%) |
Sep 2021 | - | $3.43 B(-7.4%) | $12.55 B(+6.9%) |
Jun 2021 | - | $3.71 B(+39.8%) | $11.74 B(+11.4%) |
Mar 2021 | - | $2.65 B(-3.9%) | $10.54 B(-1.9%) |
Dec 2020 | $10.75 B(+9.8%) | $2.76 B(+5.4%) | $10.75 B(+8.0%) |
Sep 2020 | - | $2.62 B(+4.4%) | $9.95 B(-0.0%) |
Jun 2020 | - | $2.51 B(-12.3%) | $9.95 B(-3.2%) |
Mar 2020 | - | $2.86 B(+45.8%) | $10.28 B(+5.0%) |
Dec 2019 | $9.79 B(-34.9%) | $1.96 B(-25.2%) | $9.79 B(+4.0%) |
Sep 2019 | - | $2.62 B(-7.6%) | $9.41 B(+1.5%) |
Jun 2019 | - | $2.84 B(+20.0%) | $9.27 B(-37.5%) |
Mar 2019 | - | $2.37 B(+49.7%) | $14.84 B(-1.3%) |
Dec 2018 | $15.03 B(+52.5%) | $1.58 B(-36.3%) | $15.03 B(-6.3%) |
Sep 2018 | - | $2.48 B(-70.5%) | $16.03 B(-0.9%) |
Jun 2018 | - | $8.41 B(+228.7%) | $16.18 B(+57.4%) |
Mar 2018 | - | $2.56 B(-1.0%) | $10.28 B(+4.4%) |
Dec 2017 | $9.85 B(+15.6%) | $2.58 B(-1.8%) | $9.85 B(+15.7%) |
Sep 2017 | - | $2.63 B(+5.0%) | $8.51 B(+2.2%) |
Jun 2017 | - | $2.51 B(+17.9%) | $8.33 B(+2.6%) |
Mar 2017 | - | $2.13 B(+70.7%) | $8.11 B(-4.8%) |
Dec 2016 | $8.52 B(-3.0%) | $1.25 B(-49.1%) | $8.52 B(-0.5%) |
Sep 2016 | - | $2.45 B(+6.8%) | $8.57 B(+1.5%) |
Jun 2016 | - | $2.29 B(-9.6%) | $8.44 B(-0.3%) |
Mar 2016 | - | $2.54 B(+96.8%) | $8.47 B(-3.6%) |
Dec 2015 | $8.79 B(-32.3%) | $1.29 B(-44.5%) | $8.79 B(-15.8%) |
Sep 2015 | - | $2.32 B(+0.1%) | $10.44 B(-11.8%) |
Jun 2015 | - | $2.32 B(-18.8%) | $11.84 B(-7.7%) |
Mar 2015 | - | $2.86 B(-3.0%) | $12.83 B(-1.1%) |
Dec 2014 | $12.98 B(+12.9%) | $2.94 B(-20.7%) | $12.98 B(+4.0%) |
Sep 2014 | - | $3.71 B(+12.1%) | $12.48 B(+9.2%) |
Jun 2014 | - | $3.31 B(+10.2%) | $11.42 B(+0.9%) |
Mar 2014 | - | $3.00 B(+22.9%) | $11.32 B(-0.1%) |
Dec 2013 | $11.49 B(-3.9%) | $2.45 B(-8.0%) | $11.33 B(-3.5%) |
Sep 2013 | - | $2.66 B(-17.2%) | $11.74 B(-2.5%) |
Jun 2013 | - | $3.21 B(+6.5%) | $12.04 B(-0.9%) |
Mar 2013 | - | $3.01 B(+5.4%) | $12.15 B(+1.6%) |
Dec 2012 | $11.96 B | $2.86 B(-3.3%) | $11.96 B(+15.9%) |
Sep 2012 | - | $2.96 B(-10.8%) | $10.32 B(-1.4%) |
Jun 2012 | - | $3.32 B(+17.5%) | $10.46 B(-1.1%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2012 | - | $2.82 B(+132.0%) | $10.58 B(-6.4%) |
Dec 2011 | $11.31 B(-8.8%) | $1.22 B(-60.8%) | $11.31 B(-11.0%) |
Sep 2011 | - | $3.11 B(-9.6%) | $12.71 B(+1.0%) |
Jun 2011 | - | $3.44 B(-3.1%) | $12.58 B(+2.5%) |
Mar 2011 | - | $3.55 B(+35.6%) | $12.28 B(-0.9%) |
Dec 2010 | $12.39 B(+18.3%) | $2.62 B(-12.3%) | $12.39 B(-1.8%) |
Sep 2010 | - | $2.98 B(-4.8%) | $12.63 B(+2.6%) |
Jun 2010 | - | $3.13 B(-14.5%) | $12.31 B(+4.7%) |
Mar 2010 | - | $3.66 B(+28.6%) | $11.75 B(+12.2%) |
Dec 2009 | $10.47 B(+7.0%) | $2.85 B(+6.9%) | $10.47 B(+10.7%) |
Sep 2009 | - | $2.66 B(+3.3%) | $9.46 B(+1.6%) |
Jun 2009 | - | $2.58 B(+8.3%) | $9.31 B(-0.9%) |
Mar 2009 | - | $2.38 B(+29.8%) | $9.40 B(-1.1%) |
Dec 2008 | $9.79 B(+26.7%) | $1.83 B(-27.1%) | $9.50 B(+6.6%) |
Sep 2008 | - | $2.52 B(-5.6%) | $8.92 B(+5.6%) |
Jun 2008 | - | $2.67 B(+7.1%) | $8.45 B(+7.9%) |
Mar 2008 | - | $2.49 B(+99.0%) | $7.83 B(+2.0%) |
Dec 2007 | $7.72 B(-6.5%) | $1.25 B(-38.8%) | $7.67 B(-12.5%) |
Sep 2007 | - | $2.04 B(-0.1%) | $8.77 B(+0.7%) |
Jun 2007 | - | $2.04 B(-12.4%) | $8.70 B(-0.2%) |
Mar 2007 | - | $2.33 B(-0.3%) | $8.72 B(+3.3%) |
Dec 2006 | $8.26 B(+15.3%) | $2.34 B(+18.4%) | $8.45 B(+7.6%) |
Sep 2006 | - | $1.98 B(-4.2%) | $7.85 B(+1.2%) |
Jun 2006 | - | $2.06 B(+0.3%) | $7.75 B(+2.9%) |
Mar 2006 | - | $2.06 B(+18.0%) | $7.54 B(+5.3%) |
Dec 2005 | $7.16 B(+7.3%) | $1.74 B(-7.6%) | $7.16 B(+1.1%) |
Sep 2005 | - | $1.89 B(+2.1%) | $7.08 B(+2.5%) |
Jun 2005 | - | $1.85 B(+10.1%) | $6.91 B(+0.8%) |
Mar 2005 | - | $1.68 B(+0.8%) | $6.86 B(+2.8%) |
Dec 2004 | $6.67 B(+11.6%) | $1.67 B(-3.0%) | $6.67 B(-0.4%) |
Sep 2004 | - | $1.72 B(-4.3%) | $6.70 B(+3.8%) |
Jun 2004 | - | $1.79 B(+20.1%) | $6.45 B(+5.4%) |
Mar 2004 | - | $1.49 B(-11.8%) | $6.12 B(+2.4%) |
Dec 2003 | $5.98 B(+1.4%) | $1.69 B(+15.3%) | $5.98 B(-7.0%) |
Sep 2003 | - | $1.47 B(+0.4%) | $6.43 B(+3.7%) |
Jun 2003 | - | $1.46 B(+8.3%) | $6.20 B(+0.3%) |
Mar 2003 | - | $1.35 B(-37.0%) | $6.18 B(-36.2%) |
Dec 2002 | $5.89 B(+20.0%) | $2.15 B(+72.8%) | $9.69 B(-655.2%) |
Sep 2002 | - | $1.24 B(-13.9%) | -$1.75 B(-167.4%) |
Jun 2002 | - | $1.44 B(-70.3%) | $2.59 B(+22.2%) |
Mar 2002 | - | $4.86 B(-152.3%) | $2.12 B(+24.6%) |
Dec 2001 | $4.91 B(+0.5%) | -$9.29 B(-266.6%) | $1.70 B(>+9900.0%) |
Sep 2001 | - | $5.58 B(+474.3%) | $0.00(-100.0%) |
Jun 2001 | - | $971.00 M(-78.1%) | -$695.00 M(+4.4%) |
Mar 2001 | - | $4.44 B(-140.4%) | -$666.00 M(-212.7%) |
Dec 2000 | $4.88 B(+5.9%) | -$10.99 B(-325.1%) | $591.00 M(-94.9%) |
Sep 2000 | - | $4.88 B(+388.1%) | $11.58 B(+72.9%) |
Jun 2000 | - | $1.00 B(-82.4%) | $6.70 B(+17.6%) |
Mar 2000 | - | $5.70 B | $5.70 B |
Dec 1999 | $4.61 B(-8.3%) | - | - |
Dec 1998 | $5.03 B | - | - |
FAQ
- What is Novartis AG annual earnings before interest & taxes?
- What is the all time high annual EBIT for Novartis AG?
- What is Novartis AG annual EBIT year-on-year change?
- What is Novartis AG quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Novartis AG?
- What is Novartis AG quarterly EBIT year-on-year change?
- What is Novartis AG TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Novartis AG?
- What is Novartis AG TTM EBIT year-on-year change?
What is Novartis AG annual earnings before interest & taxes?
The current annual EBIT of NVS is $14.65 B
What is the all time high annual EBIT for Novartis AG?
Novartis AG all-time high annual earnings before interest & taxes is $25.32 B
What is Novartis AG annual EBIT year-on-year change?
Over the past year, NVS annual earnings before interest & taxes has changed by +$4.67 B (+46.78%)
What is Novartis AG quarterly earnings before interest & taxes?
The current quarterly EBIT of NVS is $3.56 B
What is the all time high quarterly EBIT for Novartis AG?
Novartis AG all-time high quarterly earnings before interest & taxes is $15.53 B
What is Novartis AG quarterly EBIT year-on-year change?
Over the past year, NVS quarterly earnings before interest & taxes has changed by +$966.00 M (+37.24%)
What is Novartis AG TTM earnings before interest & taxes?
The current TTM EBIT of NVS is $14.65 B
What is the all time high TTM EBIT for Novartis AG?
Novartis AG all-time high TTM earnings before interest & taxes is $25.54 B
What is Novartis AG TTM EBIT year-on-year change?
Over the past year, NVS TTM earnings before interest & taxes has changed by +$4.67 B (+46.78%)